TEVA - Teva Pharmaceutical Industries Limited
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Tel Aviv,
Israel
Type: Equity
TEVA price evolution
TEVA
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3226 | $2249 | $2669 | $2143 |
| Short term investments | ||||
| Net receivables | $3408 | $3385 | $3539 | $3435 |
| Inventory | $4021 | $4051 | $4109 | $4118 |
| Total current assets | $12485 | $11425 | $12088 | $11501 |
| Long term investments | ||||
| Property, plant & equipment | $6147 | $6028 | $6130 | $6171 |
| Goodwill & intangible assets | $22564 | $22410 | $22856 | $23763 |
| Total noncurrent assets | $30994 | $30663 | $31007 | $31955 |
| Total investments | ||||
| Total assets | $43479 | $42088 | $43095 | $43456 |
| Current liabilities | ||||
| Accounts payable | $2602 | $2280 | $2508 | $2381 |
| Deferred revenue | ||||
| Short long term debt | $1672 | $1479 | $1980 | $1023 |
| Total current liabilities | $12247 | $11394 | $11843 | $10411 |
| Long term debt | $18481 | $18819 | $19036 | $20013 |
| Total noncurrent liabilities | $23106 | $23182 | $23544 | $24433 |
| Total debt | $20153 | $20298 | $21016 | $21036 |
| Total liabilities | $35353 | $34576 | $35387 | $34844 |
| Shareholders' equity | ||||
| Retained earnings | -$13534 | -$13870 | -$13950 | -$13086 |
| Other shareholder equity | -$2697 | -$2910 | -$2677 | -$2701 |
| Total shareholder equity | $7506 | $6930 | $7052 | $7861 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3226 | $2801 | $2165 | $2177 |
| Short term investments | ||||
| Net receivables | $3408 | $3696 | $4529 | $4581 |
| Inventory | $4021 | $3833 | $3818 | $4403 |
| Total current assets | $12485 | $12051 | $12573 | $13005 |
| Long term investments | ||||
| Property, plant & equipment | $6147 | $6158 | $6477 | $6855 |
| Goodwill & intangible assets | $22564 | $23903 | $27506 | $29547 |
| Total noncurrent assets | $30994 | $31955 | $35093 | $37635 |
| Total investments | ||||
| Total assets | $43479 | $44006 | $47666 | $50640 |
| Current liabilities | ||||
| Accounts payable | $2602 | $1887 | $1686 | $1756 |
| Deferred revenue | ||||
| Short long term debt | $1672 | $2109 | $1426 | $3188 |
| Total current liabilities | $12247 | $11469 | $11027 | $13164 |
| Long term debt | $18481 | $19103 | $22033 | $23210 |
| Total noncurrent liabilities | $23106 | $23846 | $25395 | $26415 |
| Total debt | $20153 | $21561 | $23459 | $26398 |
| Total liabilities | $35353 | $36109 | $36422 | $39579 |
| Shareholders' equity | ||||
| Retained earnings | -$13534 | -$12882 | -$10529 | -$10946 |
| Other shareholder equity | -$2697 | -$2838 | -$2683 | -$2399 |
| Total shareholder equity | $7506 | $7897 | $10278 | $10026 |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3850 | $3878 | $3661 | |
| Cost of revenue | $1999 | $2082 | $2079 | |
| Gross Profit | $1851 | $1796 | $1582 | |
| Operating activities | ||||
| Research & development | $253 | $240 | $234 | |
| Selling, general & administrative | $844 | $910 | $842 | |
| Total operating expenses | $1495 | $2475 | $1583 | |
| Operating income | $356 | -$679 | -$1 | |
| Income from continuing operations | ||||
| EBIT | $348 | -$611 | $36 | |
| Income tax expense | -$12 | -$16 | -$19 | |
| Interest expense | $280 | $268 | $260 | |
| Net income | ||||
| Net income | $80 | -$863 | -$205 | |
| Income (for common shares) | $80 | -$863 | -$205 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15846 | $14925 | $15878 | $16659 |
| Cost of revenue | $8200 | $7952 | $8284 | $8933 |
| Gross Profit | $7646 | $6973 | $7594 | $7726 |
| Operating activities | ||||
| Research & development | $953 | $838 | $967 | $997 |
| Selling, general & administrative | $3498 | $3445 | $3528 | $3671 |
| Total operating expenses | $7213 | $9179 | $5977 | $11337 |
| Operating income | $433 | -$2206 | $1617 | -$3611 |
| Income from continuing operations | ||||
| EBIT | $491 | -$2025 | $1686 | -$3324 |
| Income tax expense | -$7 | -$638 | $211 | -$168 |
| Interest expense | $1057 | $966 | $1058 | $834 |
| Net income | ||||
| Net income | -$559 | -$2353 | $417 | -$3990 |
| Income (for common shares) | -$559 | -$2353 | $417 | -$3990 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $429 | $80 | -$863 | -$205 |
| Operating activities | ||||
| Depreciation | $266 | $283 | $300 | $304 |
| Business acquisitions & disposals | $10 | $56 | $2 | |
| Stock-based compensation | $28 | $31 | $30 | $32 |
| Total cash flows from operations | $1184 | $5 | $324 | -$145 |
| Investing activities | ||||
| Capital expenditures | -$119 | -$149 | -$119 | -$139 |
| Investments | $419 | $324 | $369 | $319 |
| Total cash flows from investing | $301 | $184 | $302 | $181 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$500 | -$500 | -$701 | |
| Total cash flows from financing | -$576 | -$576 | -$55 | -$706 |
| Effect of exchange rate | $68 | -$33 | -$77 | $12 |
| Change in cash and equivalents | $977 | -$420 | $494 | -$658 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$559 | -$2353 | $417 | -$3990 |
| Operating activities | ||||
| Depreciation | $1153 | $1308 | $1330 | $1557 |
| Business acquisitions & disposals | $68 | $61 | $311 | |
| Stock-based compensation | $121 | $124 | $119 | $129 |
| Total cash flows from operations | $1368 | $1590 | $798 | $1216 |
| Investing activities | ||||
| Capital expenditures | -$526 | -$548 | -$562 | -$578 |
| Investments | $1431 | $1143 | $1773 | $1350 |
| Total cash flows from investing | $968 | $656 | $1523 | $863 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$1701 | -$1369 | -$2166 | -$1880 |
| Total cash flows from financing | -$1913 | -$1487 | -$2172 | -$1885 |
| Effect of exchange rate | -$30 | -$123 | -$128 | $8 |
| Change in cash and equivalents | $393 | $636 | $21 | $202 |
News
Fundamentals
| Market cap | $14.61B |
|---|---|
| Enterprise value | $31.54B |
| Shares outstanding | 1.12B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 1.43 |
| Book/Share | 9.08 |
| Cash/Share | 2.87 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 4.71 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.02 |
| Quick ratio | 0.69 |